StHealth Capital, Our #1 Ranked Emerging BDC Idea.

Newly Launched Medtech & Biotech BDC Seeking Pre-IPO Stage Investments. This is easily one of the most exciting...
video

StHealth Private Equity Medtech Fund. Alternative Investment BDC.

StHealth Capital (STHC, no symbol yet) has put together an amazing team to manage the Fund recently organized to provide investors with...
DIABASENS

Diabasens® to Launch in Europe. Innovus (INNV).

"The product will be launched initially in France, the United Kingdom, Italy, Germany and Spain through our Pan-European Amazon® store, followed by...

Former Tesla Foundation Vice Chairman Joins StHealth BDC.

St Health Capital Investment Corporation is delighted to announce Dr. Robert GW Brown FAPS, FIEE, FInstP, MAE as a key new member to our board...

Hercules BDC (HTGC) $13, to Present at FB Riley.

Hercules Capital to Discuss 2019 Growth Opportunities at the B. Riley FBR Institutional Investor Conference PALO ALTO, Calif.--(BUSINESS...

Innovus (INNV) in Silicon Review Interview.

POISED FOR INNOVATION. The Silicon Review is the world’s most trusted online and print community for business &...
internet stock review

Innovus (INNV) Conference Call Transcript.

Q1 2019 Results, 5/15/19.  Innovus Pharmaceuticals, Inc. (OTCQB:INNV) Q1 2019 Earnings Conference Call May 15, 2019 4:15 PM...

Vaccinex (VCNX) Reports First Quarter 2019 Financial Results and Provides Corporate Update.

Updated interim data from CLASSICAL-Lung study to be presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in...
internet stock review

Innovus (INNV) Conference Call Today 5/15/19 at 4:15 EST.

The Company will host a conference call on Wednesday, May 15, 2019 at 4:15 p.m. ET/1:15 p.m. PT to discuss the financial...
biotech stock review, fluticare

Innovus (INNV): Twenty-Eight Drugs in Five Years. (San Diego Reader)

(Originally published 4/25/2018) “I am very steady. I like to work slowly, but surely, to get to my goal.”...

Latest article

Dyadic, Biotech Stock Review

Dyadic (DYAI) $7.00 Called a ‘Gamechanger’ – Gets $14 Price Target.

Highly Respected Wall Street Analyst Jason Kolbert Issues $14.00 Price Target On Dyadic.
Dyadic

Investor Presentation Slides From Dyadic (DYA) $6.40.

Really, How Do We Do It? Live Short Term Chart
Tue Nature, Biotch Stock Review

True Nature Holding (TNTY) Announces New Board Member and CEO.

Lawrence M. Diamond Joins True Nature Holding, Inc. in Board, CEO Roles, Brings Career Telehealth, Healthcare and Technology Focus